News

India Eases Pharma-Grade Sugar Exports, Launches 'Source from India' to Strengthen Global Supply Role

India has approved limited annual exports of pharma-grade sugar and launched a digital sourcing platform to enhance its role in global pharmaceutical supply chains.

• By Pooja Chaturvedi Sah
• New Delhi
• Jun 18, 2025

News

In a calibrated move that reflects both export facilitation and supply control, the Indian government on June 18 permitted the export of up to 25,000 metric tonnes (MT) of pharma-grade sugar annually under the restricted category. The decision, formalised through a Directorate General of Foreign Trade (DGFT) notification, is restricted to bona fide pharmaceutical exporters and requires a special export authorisation.

This controlled liberalisation marks a balancing act—acknowledging rising international demand for pharma excipients, while preventing domestic shortages. Pharma-grade sugar, a high-purity excipient used in tablets, syrups, and drug coatings, is a critical component in both domestic drug manufacturing and export formulations.

Policy Rationale: By capping the quantity and restricting eligibility, the government signals a willingness to support export-oriented pharmaceutical players without risking internal supply pressures or price volatility in the refined sugar market.

India’s Competitive Edge in Pharma Excipients

India is not just a bulk drug hub but also a growing player in high-quality pharmaceutical inputs such as sucrose IP/USP, commonly referred to as pharma-grade sugar. Indian companies have invested significantly in meeting pharmacopoeial standards set by global regulators (IP, USP, BP), with some plants certified for ISO 9001:2008 and HACCP compliance.

Notable Players in the Segment:

M.B. Sugars & Pharmaceuticals – Specialises in stainless-steel plant-based sugar refining and sugar spheres.

Dhampur Bio Organics – Supplies to major Indian and international pharma firms.

Triveni Engineering – Employs phospho-floatation process for ultra-pure output.

Others: Bajaj Hindusthan, ModiSugar, Shreeji Pharma, and JPM Sugar LLP, among others.

Market Insight: With the global excipients market projected to grow at over 6% CAGR, India’s presence in the pharma-grade sugar niche could provide significant export revenue—especially as global supply chains seek diversified sourcing.

Trade Infrastructure: ‘Source from India’ Adds Digital Firepower

Complementing the export policy change, the DGFT has launched a new feature—‘Source from India’—on its Trade Connect ePlatform, aimed at international buyers seeking verified Indian exporters. The move is part of India’s broader push to digitally integrate trade promotion, exporter visibility, and mission-level coordination.

Through personalised micropages, exporters can display:

Product portfolios

Regulatory certifications

Contact information and company profiles

Initially launched for 3-star and higher-rated manufacturers, the portal is now expected to expand access to more exporters. Indian Missions Abroad have also been instructed to leverage the platform to respond to sourcing inquiries, especially in sectors like pharmaceuticals, agro-chemicals, and engineering goods.

Strategic View: This initiative aligns with India's goal of becoming a central node in global value chains—not just as a manufacturing base but as a credible, discoverable sourcing partner.

Implications for Indian Pharma and Export Strategy

This two-pronged announcement—the controlled export of a key pharma excipient and the digitalisation of exporter visibility—highlights a shift in India’s export strategy from quantity-driven to value-driven growth. With increased global scrutiny on pharmaceutical quality, traceability, and supply resilience, India is positioning itself as a trusted supplier in high-compliance markets.

Moreover, the combination of controlled exports and digital discoverability could give Indian exporters better access to regulated markets (such as the U.S., Europe, and Japan), where pharma-grade sugar is used in:

Coated tablets

Dry syrups

Nutraceuticals and vitamin syrups

Homeopathic sugar globules

Expert View: "With more scrutiny on the quality of pharmaceutical excipients worldwide, India’s move to formalise pharma-grade sugar exports reflects both market maturity and compliance readiness," said an industry analyst tracking pharma trade policy.

While the 25,000 MT cap on pharma-grade sugar exports may seem conservative, it marks an important policy opening for Indian manufacturers to enter or expand in regulated export markets. Combined with the ‘Source from India’ tool, the government is steadily building a framework that integrates policy control, global outreach, and quality certification—key ingredients for India's ambitions to become the pharmacy of the world not just in APIs, but also in critical pharmaceutical inputs.